Posts

Posted on

Fintech Startups Given Chance to Join ‘Hotbed of Innovation’ at 2022 FIS Fintech Accelerator

Fintech Startups Given Chance to Join ‘Hotbed of Innovation’ at 2022 FIS Fintech Accelerator

Key facts:

  • Fintech startups and growth-stage companies are encouraged to apply for the 2022 FIS Fintech Accelerator and the opportunity to accelerate the development of their innovative solutions.
  • Ten companies will be selected to present their solutions to more than 100 leading financial institutions, potential investors and industry participants.
  • April 15 is the deadline to apply for the 2022 FIS Fintech Accelerator, now in its seventh year.

JACKSONVILLE, Fla.–(BUSINESS WIRE)–
Financial technology leader FIS® (NYSE: FIS) announced today that applications are being accepted for the 2022 FIS Fintech Accelerator program, now in its seventh year.

The FIS Fintech Accelerator, in collaboration with The Venture Center (of Arkansas) and the State of Arkansas, is focused on finding and helping high-potential fintech startups and growth-stage companies accelerate the development of innovative solutions that advance the financial services industry.

Past participants of the Accelerator program have deepened relationships within the FIS network and won numerous industry awards, including Finovate’s Best in Show. They have also raised tens of millions of dollars in capital to advance their businesses and established partnerships with leading financial institutions to bring their solutions to market.

The 16-week program, consisting of a four-week incubator and 12-week Accelerator, provides a unique opportunity for ten selected fintech companies to engage and share their innovative solutions with more than 100 of FIS’ leading financial institution clients. At the conclusion of the program, each selected company will receive a monetary investment and can pitch their ideas to potential investors and industry participants at the 2022 FIS Demo Day on October 26.

The Fintech Accelerator is open to all fintech startups with established customers and recurring revenue. The program encourages applications from startups and growth-stage companies owned or operated by women and underrepresented minorities.

The 2022 program will begin in-person at The Venture Center in Little Rock, Arkansas on June 29. Applications can be completed online through April 15 and technology submissions should fall into one of these categories: Distributed Ledger Technology, Banking as a Service and Embedded Finance Solutions, AI and Machine Learning Analytics, Innovative Digital Payments, Wealth Tech, Consumer Lending Tech, and Financial Wellness.

“We’re excited to begin accepting submissions for the 2022 FIS Fintech Accelerator and encourage early- to growth-stage fintech startups to apply and pitch their ideas. The Accelerator is fueled by FIS Impact Ventures, the corporate investment division of FIS, which provides some of the best advocacy and support for fintech startups and allows selected participants to leverage the FIS distribution network and global technology ecosystem,” said Rob Lee, President, FIS Impact Ventures.

“Fintech has allowed Arkansas to be globally recognized as a hotbed of innovation and financial technology,” said Governor Asa Hutchinson. “Thanks to the FIS Fintech Accelerator program, Arkansas will welcome the next group of minds who will aim to stir the coals of innovation.”

“FIS is the premier industry leader driving innovation in the way the world banks, pays and invests,” said Wayne Miller, Executive Director of The Venture Center. “We are honored to produce the FIS Fintech Accelerator for the seventh consecutive year. Under Rob Lee’s leadership, FIS continues to widen its lead as the best advocate for fintechs seeking to leverage its global platform to improve the success of its clients. This year, 10 selected companies will have the opportunity to tap into limitless growth by working with hundreds of financial industry decision-makers, and we’re excited to explore the new cohort’s potential.”

Learn more about the FIS Fintech Accelerator at www.venturecenter.co/fisfintech.

About FIS

FIS is a leading provider of technology solutions for merchants, banks and capital markets firms globally. Our employees are dedicated to advancing the way the world pays, banks and invests by applying our scale, deep expertise and data-driven insights. We help our clients use technology in innovative ways to solve business-critical challenges and deliver superior experiences for their customers. Headquartered in Jacksonville, Florida, FIS ranks #241 on the 2021 Fortune 500 and is a member of Standard & Poor’s 500® Index. To learn more, visit www.fisglobal.com. Follow FIS on Facebook, LinkedIn and Twitter (@FISGlobal).

Kim Snider, 904.438.6278

Senior Vice President

FIS Global Marketing and Communications

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Technology Finance Security Banking Other Technology Professional Services Software Networks Internet

MEDIA:

Logo
Logo
Posted on

Joby Aviation to Report Fourth Quarter 2021 Results

Joby Aviation to Report Fourth Quarter 2021 Results

SANTA CRUZ, Calif.–(BUSINESS WIRE)–
Joby Aviation (NYSE: JOBY), a California-based company developing all-electric aircraft for commercial passenger service, today announced that it will release its fourth quarter 2021 earnings results after the market close on Thursday, March 24, 2022. Management will discuss the results on a conference call at 5:00 pm ET on Thursday, March 24, 2022. The webcast will be publicly available in the Upcoming Events section of the company website (www.jobyaviation.com). To listen by phone, please dial 1-877-407-3982 or 1-201-493-6780. A replay of the call will be available until midnight, Thursday, April 7, 2022, by dialing 1-844-512-2921 or 1-412-317-6671 and entering passcode 13726125.

About Joby Aviation

Joby Aviation, Inc. (NYSE: JOBY) is a California-headquartered transportation company developing an all-electric vertical take-off and landing aircraft which it intends to operate as part of a fast, quiet, and convenient air taxi service beginning in 2024. The aircraft, which has a maximum range of 150 miles on a single charge, can transport a pilot and four passengers at speeds of up to 200 mph. It is designed to help reduce urban congestion and accelerate the shift to sustainable modes of transit. Founded in 2009, Joby employs around 1,000 people, with offices in Santa Cruz, San Carlos, and Marina, California, as well as Washington, D.C. and Munich, Germany. To learn more, visit www.jobyaviation.com.

Forward Looking Statements

This document contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding Joby’s intentions and plans. Forward-looking statements give Joby’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “will”, “should”, “can have”, “likely” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including: Joby’s limited operating history and history of losses; its ability to launch its aerial ridesharing service and the growth of the urban air mobility market generally; Joby’s plans to operate a commercial passenger service beginning in 2024; the competitive environment in which it operates; its future capital needs; its ability to adequately protect and enforce its intellectual property rights; its ability to effectively respond to evolving regulations and standards relating to its aircraft; its reliance on a third-party suppliers and service partners; uncertainties related to Joby’s estimates of the size of the market for its aircraft and future revenue opportunities; and other important factors discussed in the section titled “Risk Factors” in its Registration Statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on October 29, 2021, and in other reports it files with or furnishes to the SEC. Any such forward-looking statements represent management’s estimates and beliefs as of the date of this press release. While Joby may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

Investors:

[email protected]

+1-831-201-6006

Media:

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Alternative Vehicles/Fuels Other Transport Automotive Air Other Energy Transport Other Automotive Alternative Energy Energy Fleet Management

MEDIA:

Posted on

Elys Game Technology Management to Host Ocean Casino Partnership Video Webinar on Friday, March 4th at 9 AM ET

Elys Game Technology Management to Host Ocean Casino Partnership Video Webinar on Friday, March 4th at 9 AM ET

Elys to provide update on Ocean Casino partnership and North American expansion

NEW YORK–(BUSINESS WIRE)–Elys Game Technology, Corp. (“Elys” or the “Company”) (Nasdaq:ELYS) (BER:3UW), an interactive gaming and sports betting technology company will host a video conference on Friday, March 4th, 2022 at 9:00 a.m. ET to update investors on the Company’s recently announced launch of its partnership with Ocean Casino Resort in Atlantic City, NJ and the Company’s North American expansion efforts.

The event registration link is as follows: Elys Game Technology Investor Update March 2022.

Details for the video conference will be posted prior to the start of the call on Elys’ Investor Relations website at https://ir.elysgame.com/news-events. For additional information please contact KCSA Strategic Communications by emailing [email protected].

About Elys Game Technology, Corp.

Elys Game Technology, Corp., is a B2B global gaming technology company operating in multiple countries worldwide, with B2C online and land-based gaming operations in Italy. Elys offers its clients a full suite of leisure gaming products and services, such as sports betting, e-sports, virtual sports, online casino, poker, bingo, interactive games and slots in Italy and has operations in six states in the U.S. market. Elys’ vision is to become a global leader in the gaming industry through the development of pioneering and innovative technology.

The Company provides wagering solutions, services online operators, casinos, retail betting establishments and franchise distribution networks. Additional information is available on our corporate website at www.elysgame.com.

Investors may also find us on Twitter @ELYS_gaming.

Elys Game Technology, Corp.

Michele Ciavarella, Executive Chairman

Tel: 1-628-258-5148

Email: [email protected]

Investor Contact:

KCSA Strategic Communications

Valter Pinto or Jack Perkins

Tel: 1-212-896-1254

Email: [email protected]

KEYWORDS: United States North America New York New Jersey

INDUSTRY KEYWORDS: Software Mobile/Wireless Entertainment Mobile Entertainment Internet Hardware Vacation Technology Destinations Travel General Entertainment Other Entertainment Casino/Gaming

MEDIA:

Logo
Logo
Posted on

Allego Enters Italy through Strategic Agreement with Tamoil Italia to Bring EV Charging to 11 Tamoil Sites

Allego Enters Italy through Strategic Agreement with Tamoil Italia to Bring EV Charging to 11 Tamoil Sites

PARIS & ARNHEM, Netherlands & NEW YORK–(BUSINESS WIRE)–
Allego Holding B.V. (“Allego” or “the “Company”), a leading pan-European electric vehicle charging network that announced a business combination with Spartan Acquisition Corp. III (“Spartan”) (NYSE: SPAQ), today announced that it has entered into a strategic agreement with Tamoil Italia, a leading fuel energy provider within the European downstream oil and gas sector, to develop 11 ultra-fast and fast charging locations throughout Italy at pre-existing Tamoil sites.

Allego has agreed to develop ten ultra-fast charging sites and one fast-charging site across northern Italy. Notably, three of these locations are set to be in Milan. The lease contract is for a 25-year term.

“We are very pleased to enter the Italian market to support the development of high-powered charging sites in Italy, a country with a long history of automotive innovation,” commented Mathieu Bonnet, CEO of Allego. “We look forward to our collaboration with Tamoil and to helping bring sustainable transportation to this region as Europe’s demand for charging infrastructure continues to grow with increasing numbers of electric vehicles on the road. Allego now operates in over 16 countries, and we are eager to continue extending our geographic footprint across Europe to deliver electric charging infrastructure as a truly pan-European company.”

“The collaboration with Allego is consistent with our commitment to constantly improve services for customers, offering charging solutions for e-mobility,” said Silvia Gadda, Sales & Marketing Manager of Tamoil Italia. “We are excited to partner with one of the leading fast-charging networks in Europe to ensure that our EV customers receive topline service whenever they seek to charge their vehicles.”

About Allego

Allego delivers charging solutions for electric cars, motors, buses, and trucks, for consumers, businesses, and cities. Allego’s end-to-end charging solutions make it easier for businesses and cities to deliver the infrastructure drivers need, while the scalability of our solutions makes us the partner of the future. Founded in 2013, Allego is a leader in charging solutions, with an international charging network comprising more than 28,000 charge points operational throughout Europe – and proliferating. In 2018, the Company was acquired by Meridiam, a global long-term sustainable infrastructure developer and investor, which provided necessary capital to enable the expansion of Allego’s existing global network, services and technologies. Allego’s charging solutions are connected to our proprietary platform, EV-Cloud, which gives our customers and us a complete portfolio of features and services to meet and exceed market demands. We are committed to providing independent, reliable, and safe charging solutions, agnostic of vehicle model or network affiliation. At Allego, we strive every day to make EV charging easier, more convenient, and more enjoyable for all.

About Tamoil Italia

Tamoil Italia S.p.A., part of Oilinvest (Netherlands) B.V., an international operator in the downstream sector, is a lean and dynamic company that operates with highly efficient processes in the Italian oil downstream with the aim of developing its business in a profitable and sustainable way. Maintaining high standards of quality and convenience Tamoil focuses on the supply of finished products, on logistics and distribution through a network of about 1,500 service stations throughout Italy and on wholesale sales of both automotive fuels, destined to consumer market and petroleum marketers and jet fuel to supply the main Italian airports.

Forward-Looking Statements.

All statements other than statements of historical facts contained in this press release (“Press Release”) are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,,” “project,” “forecast,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” “target” or other similar expressions (or the negative versions of such words or phrases) that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the benefits of the strategic agreement and expansion plans. These statements are based on various assumptions, whether or not identified in this Press Release, and on the current expectations of Allego’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and such differences may be material. Many actual events and circumstances are beyond the control of Allego. These forward-looking statements are subject to several risks and uncertainties, including (i) changes in domestic and foreign business, market, financial, political, and legal conditions; (ii) risks related to the rollout of Allego’s business strategy and the timing of expected business milestones; (iii) risks related to the consummation of the proposed business combination with Spartan being delayed or not occurring at all; (iv) risks related to political and macroeconomic uncertainty; (v) the risk that the operating and strategic initiatives described in the Press Release are delayed or do not occur at all; (vi) the risk that the benefits to Allego of the operating and strategic initiatives described in the Press Release are delayed, are less than anticipated or do not occur at all; and (vii) the impact of the global COVID-19 pandemic, including its impact on any of the foregoing risks. If any of these risks materialize or Allego’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Allego does not presently know or that Allego currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Allego’s expectations, plans, or forecasts of future events and views as of the date of this Press Release. Allego anticipates that subsequent events and developments will cause Allego’s assessments to change. However, while Allego may elect to update these forward-looking statements at some point in the future, Allego expressly disclaims any obligation to do so unless required by applicable law. These forward-looking statements should not be relied upon as representing Allego’s assessments as of any date after this Press Release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

For Allego

Investors

[email protected]

Media

[email protected]

For Meridiam

FTI Consulting

[email protected]

For Spartan Acquisition Corp. III

Investors

[email protected]

Media

[email protected]

KEYWORDS: United States France North America Italy Europe Netherlands New York

INDUSTRY KEYWORDS: Software Utilities Oil/Gas Alternative Energy Transportation Energy Technology Travel Other Transport Transport Automotive Manufacturing Logistics/Supply Chain Management Manufacturing

MEDIA:

Logo
Logo
Posted on

Points extends strategic collaboration with Marriott Bonvoy as exclusive global loyalty commerce technology provider; implements new Top-Up product

TORONTO, March 03, 2022 (GLOBE NEWSWIRE) — Global leader in powering loyalty commerce, Points (NASDAQ: PCOM) (TSX: PTS) is pleased to announce the extension of its relationship with Marriott Bonvoy as the program’s exclusive loyalty commerce technology provider of purchasing and gifting Marriott Bonvoy points. Points, through its loyalty solutions and data-driven marketing expertise, has proven to increase member engagement and generate additional revenue for Marriott Bonvoy over the course of their strategic collaboration, which began in 2006. The extension of the collaboration coincides with the introduction of a new solution for Marriott Bonvoy members, powered by Points.

Fully integrated within Marriott’s direct booking channels, Top-Up makes it easy for Marriott Bonvoy members to confirm their next stay sooner using their Marriott Bonvoy points. Members can easily see any shortfall in their points balance when they have selected their next points redemption stay in the booking flow. The new solution calculates how many additional points members need to realize their point redemption goal right away and allows members to purchase the required number of points seamlessly as part of the booking process.

The new solution will also enable Marriott to enhance its personalized loyalty marketing campaigns with varied promotional constructs, enabling members to take advantage of offers that weren’t previously available to them.

Rob MacLean, CEO of Points, said, “We are delighted to be extending our longstanding collaboration with Marriott with the implementation of one of our latest products. Loyalty solutions like Top-Up offer consumers more flexibility when accruing and redeeming their rewards – thus enhancing the member experience for loyalty programs, like Marriott Bonvoy, and helping them accelerate their travel recovery overall.”

David Solomon, Marriott’s VP of Loyalty Product Development & Management said, “We are thrilled to be expanding our relationship with Points. It will enable Marriott Bonvoy to offer our members more personalized service and points purchase options when booking a redemption stay at any of our more than 7,900 participating properties.”

Points already powers Marriott Bonvoy’s Buy and Gift features that enable members to purchase additional points or gift them to friends and family via a secure real-time integration. Data-driven marketing strategies devised and implemented by Points for Marriott Bonvoy have resulted in a significant uplift in transactions, even during the reduced period of travel that ensued at the onset of the pandemic.

For more information on how Points can unlock loyalty programs’ potential, visit points.com.

About Points.com Inc.

Points (TSX: PTS) (Nasdaq: PCOM) is a trusted partner to the world’s leading loyalty programs, leveraging its unique Loyalty Commerce Platform to build, power, and grow a network of ways members can get and use their favourite loyalty currency. Our platform combines insights, technology, and resources to make the movement of loyalty currency simpler and more intelligent for nearly 60 reward programs worldwide. Founded in 2000, Points is headquartered in Toronto with teams operating around the globe.

For more information, visit Points.com.



Media Relations:
Rachel Goldrick
[email protected]  

Posted on

LSB Industries, Inc. Announces Proposed Private Offering of Senior Notes

LSB Industries, Inc. Announces Proposed Private Offering of Senior Notes

OKLAHOMA CITY–(BUSINESS WIRE)–
LSB Industries, Inc. (NYSE: LXU) (“LSB”) today announced that it intends to offer, subject to market and other conditions, $175,000,000 in aggregate principal amount of its 6.250% Senior Secured Notes due 2028 (the “Notes”) for sale in a private offering to eligible purchasers. The Notes constitute a further issuance of the 6.250% Senior Secured Notes due 2028, of which $500 million aggregate principal amount was issued on October 14, 2021. The Notes will be guaranteed on a senior secured basis by all of LSB’s existing subsidiaries and by certain of LSB’s future domestic wholly owned subsidiaries.

LSB intends to use the net proceeds from this offering to pursue strategic acquisition opportunities, to fund organic growth (including debottlenecking to increase production capacity and other growth projects) and for general corporate purposes. Pending such application of the net proceeds of this offering, they may be invested in highly rated money market funds, U.S. government securities, treasury bills or short-term commercial paper.

This press release is neither an offer to sell nor a solicitation of an offer to buy the Notes or any other securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. The Notes and the guarantees thereof have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and may not be offered or sold in the United States absent registration or applicable exemption from the registration requirements under the Securities Act and applicable state securities laws. The Notes are expected to be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act and to non-U.S. persons outside of the United States pursuant to Regulation S under the Securities Act. This press release is being issued in accordance with Rule 135c under the Securities Act.

About LSB Industries, Inc.

LSB Industries, Inc., headquartered in Oklahoma City, Oklahoma, manufactures and markets chemical products for the agricultural, industrial, and mining markets. The Company owns and operates three multi plant facilities in El Dorado, Arkansas, Cherokee, Alabama and Pryor, Oklahoma, and operates a facility on behalf of a global chemical company in Baytown, Texas. LSB’s products are sold through distributors and directly to end customers throughout the United States and parts of Mexico and Canada.

Forward-Looking Statements

Statements in this release that are not historical are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance including the effects of the COVID-19 pandemic and anticipated performance based on our growth and other strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or actual achievements to differ materially from the results, level of activity, performance or anticipated achievements expressed or implied by the forward-looking statements. Significant risks and uncertainties may relate to, but are not limited to, the offering of the Notes may not ultimately be completed because of general market conditions or other factors, business and market disruptions related to the COVID-19 pandemic, market conditions and price volatility for our products and feedstocks, as well as global and regional economic downturns, including as a result of the COVID-19 pandemic, that adversely affect the demand for our end-use products; disruptions in production at our manufacturing facilities; and other financial, economic, competitive, environmental, political, legal and regulatory factors. These and other risk factors are discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2021.

Cheryl Maguire, Executive Vice President & CFO

(405) 510-3524

Fred Buonocore, CFA, Vice President of Investor Relations

(405) 510-3550

[email protected]

KEYWORDS: United States North America Oklahoma

INDUSTRY KEYWORDS: Chemicals/Plastics Mining/Minerals Manufacturing Agriculture Natural Resources Other Manufacturing

MEDIA:

Logo
Logo
Posted on

Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics

PR Newswire

MELBOURNE, Australia, March 3, 2022 /PRNewswire/ — Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced it has executed a license agreement with Monash University (‘Monash University’ or ‘Monash’) to develop a novel treatment that combines Virtual Reality (‘VR’) and psychedelics. This marks the initiation of a second clinical psychedelic therapy program.

Incannex has executed an exclusive, global license in perpetuity over an immersive therapeutic VR environment that has been developed by BrainPark, a state-of-the-art clinical research platform at Monash University’s Turner Institute for Brain and Mental Health. The license allows Incannex to investigate the use of the VR therapy tool in combination with a psychedelic drug to develop a new treatment for severe forms of one or more anxiety disorders.

The established VR treatment uses an exposure-based approach, providing triggering stimuli in a graded and controlled manner (Exposure and Response Prevention or ERP). Alongside specialised clinical support and the administration of a psychedelic drug, this approach may allow for the development of new skills, changes in mental and biological responses to triggering stimuli, and reductions in pathological symptoms and behaviours.

The associated research and development project will be funded by Incannex and undertaken by Monash, led by Dr Paul Liknaitzky (Head, The Clinical Psychedelic Research Lab, Turner Institute and Department of Psychiatry, Monash) and Professor Murat Yücel (Director, BrainPark, Turner Institute, Monash), in collaboration with Professor Suresh Sundram (Head, Department of Psychiatry, Monash) and Dr Rebecca Segrave (Deputy Director, BrainPark, Monash).

Three license fees are outlined in the agreement and payable upon the decision by Incannex to proceed to subsequent phases of the research program. The parties are working towards a research agreement for the first of these trials, which will assess optimal dose, safety, and tolerability of the combination treatment method. Commercial aspects of the license agreement are detailed in Appendix A.

CEO and Managing Director of Incannex, Mr. Joel Latham, said; “We’re delighted to have commenced this exciting project and to have expanded our partnership with Monash. The combination of psychedelic compounds with an evidence-based VR therapy is a leading edge in the field of mental health treatments. We look forward to providing more detail about the project in due course when clinical trial planning has been finalised.”

About Incannex Healthcare Limited
Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of generalised anxiety disorder (GAD), obstructive sleep apnoea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis and inflammatory bowel disease. U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication represents major global markets and currently have no, or limited, existing registered pharmacotherapy (drug) treatments available to the public. IHL has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners.
Website: www.incannex.com.au
Investors: [email protected]

Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations and estimates, as well as the beliefs and assumptions of management. The forward-looking statements included in this press release represent Incannex’s views as of the date of this press release. Incannex anticipates that subsequent events and developments may cause its views to change. Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Incannex’s views as of any date after the date of this press release.

Contact Information

Incannex Healthcare Limited
Mr Joel Latham
Managing Director and Chief Executive Officer
+61 409 840 786
[email protected]  

US IR Contact
Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected] 

Appendix A

Licence Fees and Royalties

The grant of the license is conditional on the payment of licence fees and royalties that Incannex will pay to Monash as follows:

  • A$300,000 on execution of the license agreement,
  • A$250,000 on execution of a research agreement between Incannex and Monash concerning a second clinical trial,
  • A$250,000 on execution of a research agreement between Incannex and Monash concerning a third clinical trial, and
  • a royalty of 7.5% of net sales, subject to successful commercialisation of a therapy.

 

Cision View original content:https://www.prnewswire.com/news-releases/incannex-executes-license-agreement-with-monash-university-to-develop-a-combination-treatment-using-virtual-reality-and-psychedelics-301494760.html

SOURCE Incannex Healthcare Limited

Posted on

Recursion Provides Updated Guidance on Clinical Trial Starts

PR Newswire


SALT LAKE CITY
, March 3, 2022 /PRNewswire/ — Recursion (NASDAQ: RXRX) today provided updated guidance on clinical trial starts:

  • Recursion’s leadership team has decided that conducting a dose optimization study in a sheep efficacy model of Tay-Sachs disease is prudent and in the best interest of patients before enrolling infants in a Phase 2 trial of REC-3599 in the ultra-rare indication infantile GM2 gangliosidosis. This decision will delay the GM2 Phase 2 trial start by approximately 2 years.
  • Recursion’s Phase 2 trial of REC-994 in Cerebral Cavernous Malformation is on track and we expect to enroll the first patient in the coming weeks.
  • The Phase 2 portion of Recursion’s adaptive Phase 2/3 trial of REC-2282 in Neurofibromatosis Type 2 is on track to enroll in Q2.
  • Recursion’s Phase 2 trial of REC-4881 in Familial Adenomatous Polyposis is expected to enroll the first patient in either Q2 or potentially Q3, 2022 due to challenges with site opening presented by the Covid-19 Omicron variant.
  • Preparations for Recursion’s Phase 1 study of REC-3964 in recurrent C. difficile colitis are on track, and we expect to begin enrollment in the second half of 2022.

About Recursion

Recursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology. Enabling its mission is the Recursion Operating System, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets, the Recursion Data Universe. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset the Recursion Map, a collection of hundreds of billions of searchable inferences across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine. 

The company is proudly headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn. 

Media Contact

[email protected]

Investor Contact

[email protected]

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding Recursion’s mission; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; expansion of facilities and expected uses; workforce growth; employee stock trading plans; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; the impact of the COVID-19 pandemic and force majeure events; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/recursion-provides-updated-guidance-on-clinical-trial-starts-301494663.html

SOURCE Recursion

Posted on

Fair Place Finance Selects Broadridge’s Blockchain-based SRD II Disclosure Solution

PR Newswire

NEW YORK and LONDON and WARSAW, Poland and LODZ, Poland, March 3, 2022 /PRNewswire/ — To support its new obligations under the Shareholder Rights Directive (SRD II), WealthSeed, a breakthrough digital application for easy investing and personal finance in Poland launched by Fair Place Finance S.A., announced it will utilize a blockchain-based disclosure solution from global Fintech leader, Broadridge Financial Solutions, Inc. (NYSE:BR).

WealthSeed will use Broadridge’s new Shareholder Disclosure Hub, an industry-wide digital solution that uses the latest API- and blockchain-based technologies, to address SRD II’s new shareholder disclosure requirements and provide class-leading data security for WealthSeed’s business in Poland and other European markets over time.

“SRD II has pushed forward corporate governance standards across Europe, while transforming market transparency through a secure and efficient disclosure process,” said Michał Antoniak, Chief Legal and Compliance Officer, WealthSeed and Fair Place Finance. “With Broadridge as our trusted go-to partner, we have been able to leverage their unique depth of expertise and get ahead of the SRD II regulation’s mandatory disclosure requirements, safe in the knowledge that we are in line with Europe’s data protection legislation.”

“We are delighted to be supporting WealthSeed, enabling them to simplify and reduce the cost of compliance for their SRD II shareholder disclosure requirements, and mitigate the risk of compliance breaches associated with a failure to forward or respond to a request,” said Demi Derem, GM, International Investor Communication Solutions at Broadridge. “By taking advantage of our innovative platform, the firm will be able to handle complex disclosure requests quickly and efficiently.”

Broadridge’s Shareholder Disclosure Hub is another example of Broadridge’s commitment to enabling the democratization of investing, helping companies better connect with investors and improve corporate governance.

About Broadridge

Broadridge Financial Solutions (NYSE: BR), a global Fintech leader with $5 billion in revenues, provides the critical infrastructure that powers investing, corporate governance, and communications to enable better financial lives. We deliver technology-driven solutions that drive business transformation for banks, broker-dealers, asset and wealth managers and public companies. Broadridge’s infrastructure serves as a global communications hub enabling corporate governance by linking thousands of public companies and mutual funds to tens of millions of individual and institutional investors around the world. Our technology and operations platforms underpin the daily trading of more than $9 trillion of equities, fixed income and other securities globally. A certified Great Place to Work®, Broadridge is part of the S&P 500® Index, employing over 13,000 associates in 21 countries. For more information about us, please visit broadridge.com.

About WealthSeed

WealthSeed is a breakthrough platform for easy investing and personal finance in Central and Eastern Europe, headquartered in Poland. WealthSeed allows customers to manage their wealth in a single convenient mobile app with free investment accounts in key currencies, low FX rates and access to stocks, ETFs, and mutual funds from all around the world and soon managed portfolios based on BlackRock funds. WealthSeed is a registered trademark of Fair Place Finance S.A. a regulated investment and payment firm licensed and supervised by the Polish Financial Services Commission (KNF).

Investors:
W. Edings Thibault
Investor Relations
+ 1 516-472-5129
[email protected]

Media:

Gregg Rosenberg

Corporate Communications
+1 212-918-6966
[email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fair-place-finance-selects-broadridges-blockchain-based-srd-ii-disclosure-solution-301495011.html

SOURCE Broadridge Financial Solutions, Inc.

Posted on

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care

The pioneer psychedelic therapy company is partnering with the rapidly growing online mental health platform to create a comprehensive mental health offering for consumers

PR Newswire

TORONTO, March 3, 2022 /PRNewswire/ — Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic-assisted psychotherapy, today announced a strategic partnership with Cerebral, the fastest growing online mental health platform. The companies are launching a partnership where Cerebral clinicians can refer qualified clients to Field Trip Health’s ketamine assisted therapy, while Field Trip will connect potential clients seeking general psychiatry and teletherapy services to Cerebral. This end-to-end solution will provide personalized treatment solutions for those seeking to improve their mental health.

Field Trip Health currently has clinics operating in eight major U.S. cities, making it the largest provider of psychedelic-assisted therapies in North America. With this partnership, Field Trip Health patients will have access to services beyond psychedelic treatments and can now access a holistic offering of mental health treatments through Cerebral.

“Our partnership with Cerebral will lower the barriers of entry into ketamine assisted therapy for many people who have solely been exposed to generalized psychiatry or might have not been presented with an alternative of exploring a healing journey propelled through psychedelics,” said Ronan Levy, Field Trip’s Executive Chairman. “We’re excited to be Cerebral’s preferred platform to refer patients to. Together we will help change the mental health landscape by bringing together teletherapy, telepsychiatry, and psychedelic-assisted therapy and offer more comprehensive benefits to consumers’ mental health.”

Cerebral’s mission is to improve access to long-term, high-quality comprehensive mental health care through affordable plans on their online mental health platform which provides comprehensive care including therapy, counseling, and medication management. Cerebral’s platform allows members to schedule and meet with their care team online and provides medication management and delivery straight to your door.

“The recent shift in the mental health landscape has resulted in a need for modernized, digitized, and personalized solutions. At its core, Cerebral believes that everyone deserves access to individualized, non-judgmental mental health care,” added Dr. David Mou, Cerebral’s Chief Medical Officer. “We’re constantly searching for novel ways to work towards that goal, which is why we chose to partner with Field Trip, a like-minded company with an aligning ethos that brings psychedelic-assisted psychotherapy to the table for our clients,”

About Field Trip Health Ltd.

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at: www.fieldtriphealth.com

Follow us on Twitter and Instagram: @fieldtriphealth

About Cerebral

Cerebral’s mission is simple and straightforward: To improve access to long-term, high-quality mental health care to all. Unlike traditional mental health care, Cerebral is accessible, convenient, affordable, and free of stigma. With several full-service monthly subscription plans to choose from, members receive online access to prescribing providers, behavioral counselors, and talk therapists—all from the comfort of home or anywhere else with an internet connection. Visits are done via video chat, and members can message their care team directly. Members can even receive medications delivered straight to their door (if prescribed). Cerebral was founded and launched in January 2020 by CEO Kyle Robertson. For more information, visit www.cerebral.com

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

Cautionary Note Regarding Forward-Looking Information.

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including commencement, uptake and success of the referral relationship between Cerebral and Field Trip, factors affecting the medical clinic industry, market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. For a more detailed discussion of risks and other factors, see Field Trip’s amended Annual Information Form dated July 16, 2021 under the heading “Risk Factors”, or otherwise disclosed in the public filings made with applicable securities regulatory authorities and available under Field Trip’s SEDAR and EDGAR profiles.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.

Neither the Toronto Stock Exchange nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/field-trip-health-and-cerebral-partner-to-provide-end-to-end-mental-health-care-301494788.html

SOURCE Field Trip Health